TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from AnaptysBio ( (ANAB) ).
On November 21, 2025, AnaptysBio announced an amendment to its Stock Repurchase Plan, allowing for an additional $100 million in stock buybacks, supplementing the $6.4 million remaining under the existing $75 million plan. This strategic move is set against the backdrop of AnaptysBio’s anticipated financial position, expecting to end 2025 with approximately $300 million in cash and investments, bolstered by a potential $75 million milestone payment from GSK. The repurchase plan, expiring on March 31, 2026, reflects AnaptysBio’s efforts to enhance shareholder value while navigating market conditions and corporate strategies.
The most recent analyst rating on (ANAB) stock is a Hold with a $37.00 price target. To see the full list of analyst forecasts on AnaptysBio stock, see the ANAB Stock Forecast page.
Spark’s Take on ANAB Stock
According to Spark, TipRanks’ AI Analyst, ANAB is a Neutral.
AnaptysBio’s overall stock score is primarily impacted by its weak financial performance, characterized by significant losses and a precarious balance sheet. While technical indicators show positive momentum, the negative valuation metrics due to ongoing losses further weigh down the score.
To see Spark’s full report on ANAB stock, click here.
More about AnaptysBio
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The company’s pipeline includes treatments such as rosnilimab for rheumatoid arthritis, ANB033 for celiac disease, and ANB101, a BDCA2 modulator. AnaptysBio has also out-licensed therapeutic antibodies to other companies, including a PD-1 antagonist to GSK and an IL-36R antagonist to Vanda Pharmaceuticals.
Average Trading Volume: 580,403
Technical Sentiment Signal: Buy
Current Market Cap: $1.02B
For a thorough assessment of ANAB stock, go to TipRanks’ Stock Analysis page.